Oramed Pharmaceuticals Inc (ORMP)

[Fmello]

My guess is that the lion's share of Oramed's target market would be prediabetics and diabetics that are using medications to lower their A1c levels so that they eventually won't have to move up to injecting themselves with insulin. This was mentioned at 41 minutes into the Q&A:

"And you know that's an important question because I think there is going to be utility for type-1 patients and the company is committed to doing a trial in type-1 diabetes. I doubt that it will replace injected insulin. That's very unlikely because you need larger doses of mealtime insulin. But what it can do is help to insulinize the liver and this can be part of reducing the overall risk of hypogylcemia in type-1 patients."

@ 53:42 in the same video, Dr. Peters is asked who would be the best candidates for an oral insulin product if Oramed gets FDA approval. Her response:

I'll go to the extremes: So if someone is on a pump...if anyone is on a therapy and doing well, I'm wildly unlikely to change it. But this gets driven by patient preference. If somebody's on an insulin pump, they need both prandial and basal insulin and they are not going to be put on this but anyone where I'm thinking of a transition if they need insulin or if they're on basal insulin already and they want to go to this, then I would certainly consider it.

Now, what I don't know in all honesty is does it mean if somebody's on 40 units of injected insulin, is it going to take away that injected insulin need or is going to be 20 units? So we will probably look at it at units per kilogram per day but I want to get a sense of how much is needed.

If that single pill each night allows a diabetic from not needing to take 40 units of insulin injections, then that would be amazing for diabetics and stockholders!